The first two candidates reached phase three trials : one from the University of Oxford and AstraZeneca, the other from China. Both appear safe and produce immune responses, according to preliminary results published today in The Lancet.
A vaccine from Moderna, the U.S. biotech firm, is heading into phase three trials after similarly encouraging initial results.
There are at least 16 other vaccines currently in clinical trials in Australia, France, Germany, India, Russia, South Korea, the U.K., the U.S. and China, which is experimenting with a variety of vaccine types and has five candidates already in trials. Axios